This site is intended for healthcare professionals
Image of AI generated blood clot formation that would require pharmacological treatments available for various vascular conditions, such as anticoagulants, anti platelet agents, and vasodilators
Antiplatelet therapy in ACS: Choices and Controversies

ESC 2022 Highlights

Read time: 10 mins
Last updated:21st Sep 2022
Published:2nd Nov 2022

The latest in Acute Coronary Syndrome from ESC 2022

From the 2022 European Society of Cardiology (ESC) congress in Barcelona, receive original content on developments in acute coronary syndrome (ACS) treatments, focusing on international guideline updates, and antiplatelet therapies such as P2Y12 inhibitors.

Interview with Professor Magdy Abdelhamid

Overview of Acute Coronary Syndrome: Signs, pathophysiology, and epidemiology

In this short video clip, Professor Magdy Abdelhamid (Cardiology Department at the Faculty of Medicine, Cairo University, Egypt) summarises the common signs and markers of pathophysiology of ACS. He also surveys prevalence and incidence data on ACS.

Guideline recommendations for anti-platelet therapy for ACS

Professor Abdelhamid reviews criteria for the use of antiplatelet therapy for people with ACS, including beyond the recommended twelve months. Risk of bleeding, he emphasises, should be assessed using a variety of clinical measures, and is higher in people above the age of 65, people with diabetes, among other factors. Watch the video to learn more.

Anti-platelet therapy options for Acute Coronary Syndrome

Watch the video below to learn options for anti-platelet therapy for ACS. Professor Abdelhamid reviews the use of newer options for patients, such as aspirin and P2Y12 inhibitors, and extended dual antiplatelet therapy (DAPT) for people with ACS at high-risk of ischaemic events. He summarises treatment goals for ACS.

*300 milligram1.

New clinical trial data for ACS and anti-platelet therapy, presented at ESC 2022

ESC 2022 was an opportunity for investigators to present recent clinical trial data on anti-platelet efficacy and safety for ACS. In this video summary, Professor Abdelhamid highlights some of these important findings.

Meet the expert

Professor Magdy AbdelhamidProfessor Magdy Abdelhamid

Magdy Abdelhamid is a Professor and Chairman of the Cardiology Department at the Faculty of Medicine, Kasr El Ainy, Cairo University, Egypt. He is a consultant cardiologist with more than 30 years of clinical experience, and has a particular interest in heart failure and coronary intervention. Professor Abdelhamid is the Past President of the Egyptian Society of Cardiology (2018–2020), and Chairman of their working group on heart failure, and a Board member of the Society. He is a Board Member of the Heart Failure Association of the ESC (2020-2022), Co-Chair of the Acute Heart Failure Scientific Committee of HFA, ESC (2020–2022), and Co-Chair of the Valvular Heart Disease Scientific Committee of HFA, ESC (2020–2022). Professor Abdelhamid is a member of the Committee of Practice Guidelines, ESC (2020–2022). Currently, Professor Abdelhamid is nominated as Co-Chair of the Educational Committee of the HFA, ESC (2022–2024), and Board member of the Educational Committee of the ESC (2022–2024).

Professor Abdelhamid is a Fellow of the American College of Cardiology (FACC), The European Society of Cardiology (FESC), the Royal College of Physicians and Surgeons (FRCP) of Glasgow, European Heart Failure Association (FHFA), and the Society for Cardiovascular Angiography and Interventions (FSCAI).

Disclosures

Professor Abdelhamid has no disclosures to report.

Reference

  1. Fox KAA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, et al. Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome. Circulation. 2004;110(10):1202–1208.
Welcome:
Updates in your area
of interest
Articles your peers
are looking at
Bookmarks
saved
Days to your
next event